دورية أكاديمية
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
| العنوان: | Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. |
|---|---|
| المؤلفون: | Parikh AR; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Van Seventer EE; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Siravegna G; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Hartwig AV; Guardant Health, Inc, Redwood City, California., Jaimovich A; Guardant Health, Inc, Redwood City, California., He Y; Guardant Health, Inc, Redwood City, California., Kanter K; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Fish MG; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Fosbenner KD; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Miao B; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts., Phillips S; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts., Carmichael JH; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts., Sharma N; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts., Jarnagin J; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Baiev I; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Shah YS; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Fetter IJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Shahzade HA; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Allen JN; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Blaszkowsky LS; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Clark JW; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Dubois JS; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Franses JW; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Giantonio BJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Goyal L; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Klempner SJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Nipp RD; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Roeland EJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Ryan DP; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Weekes CD; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Wo JY; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Hong TS; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Bordeianou L; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts., Ferrone CR; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts., Qadan M; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts., Kunitake H; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts., Berger D; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts., Ricciardi R; Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts., Cusack JC; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts., Raymond VM; Guardant Health, Inc, Redwood City, California., Talasaz A; Guardant Health, Inc, Redwood City, California., Boland GM; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts., Corcoran RB; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. rbcorcoran@partners.org. |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Oct 15; Vol. 27 (20), pp. 5586-5594. Date of Electronic Publication: 2021 Apr 29. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Circulating Tumor DNA/*blood , Colorectal Neoplasms/*blood , Colorectal Neoplasms/*surgery , Neoplasm, Residual/*blood, Adult ; Aged ; Aged, 80 and over ; Colorectal Neoplasms/pathology ; Female ; Hematologic Tests ; Humans ; Male ; Middle Aged ; Prospective Studies |
| مستخلص: | Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations to facilitate ctDNA detection, requiring tumor and blood. We evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection. Experimental Design: A total of 252 prospective serial plasma specimens from 103 patients with colorectal cancer undergoing curative-intent surgery were analyzed and correlated with recurrence. Results: Of 103 patients, 84 [stage I (9.5%), II (23.8%), III (47.6%), IV (19%)] had evaluable plasma drawn after completion of definitive therapy, defined as surgery only ( n = 39) or completion of adjuvant therapy ( n = 45). In "landmark" plasma drawn 1-month (median, 31.5 days) after definitive therapy and >1 year follow-up, 15 patients had detectable ctDNA, and all 15 recurred [positive predictive value (PPV), 100%; HR, 11.28 ( P < 0.0001)]. Of 49 patients without detectable ctDNA at the landmark timepoint, 12 (24.5%) recurred. Landmark recurrence sensitivity and specificity were 55.6% and 100%. Incorporating serial longitudinal and surveillance (drawn within 4 months of recurrence) samples, sensitivity improved to 69% and 91%. Integrating epigenomic signatures increased sensitivity by 25%-36% versus genomic alterations alone. Notably, standard serum carcinoembryonic antigen levels did not predict recurrence [HR, 1.84 ( P = 0.18); PPV = 53.9%]. Conclusions: Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection. See related commentary by Bent and Kopetz, p. 5449 . (©2021 American Association for Cancer Research.) |
| التعليقات: | Comment in: Clin Cancer Res. 2021 Oct 15;27(20):5449-5451. (PMID: 34389607) Comment in: Clin Cancer Res. 2021 Dec 1;27(23):6613. (PMID: 34853074) Comment in: Clin Cancer Res. 2021 Dec 1;27(23):6614-6615. (PMID: 34853075) |
| References: | Ann Oncol. 2019 Mar 1;30(3):358-359. (PMID: 30649226) Clin Cancer Res. 2017 Sep 15;23(18):5437-5445. (PMID: 28600478) Nature. 2019 Jun;570(7761):385-389. (PMID: 31142840) World J Gastrointest Oncol. 2020 Aug 15;12(8):808-832. (PMID: 32879661) Ann Oncol. 2020 Sep;31(9):1266-1267. (PMID: 32371122) JAMA Oncol. 2019 Aug 1;5(8):1124-1131. (PMID: 31070691) Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. (PMID: 28252003) Nat Rev Cancer. 2017 Apr;17(4):223-238. (PMID: 28233803) CA Cancer J Clin. 2020 May;70(3):145-164. (PMID: 32133645) Nature. 2018 Nov;563(7732):579-583. (PMID: 30429608) Clin Cancer Res. 2019 Oct 15;25(20):6026-6034. (PMID: 31088829) Sci Transl Med. 2016 Jul 6;8(346):346ra92. (PMID: 27384348) Sci Transl Med. 2019 Aug 7;11(504):. (PMID: 31391323) JAMA Oncol. 2019 Dec 1;5(12):1710-1717. (PMID: 31621801) PLoS One. 2015 Oct 16;10(10):e0140712. (PMID: 26474073) Nat Med. 2017 Jun;23(6):703-713. (PMID: 28481359) Ann Oncol. 2019 Nov 1;30(11):1804-1812. (PMID: 31562764) Cell. 2017 Feb 9;168(4):571-574. (PMID: 28187279) J Clin Oncol. 2018 Oct 30;:JCO2018789032. (PMID: 30376428) Clin Cancer Res. 2018 Sep 15;24(18):4437-4443. (PMID: 29567812) Clin Cancer Res. 2018 Oct 1;24(19):4633-4642. (PMID: 29703819) Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385) Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134. (PMID: 26661580) Int J Cancer. 2021 Feb 15;148(4):1014-1026. (PMID: 32984952) |
| معلومات مُعتمدة: | P50 CA127003 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Circulating Tumor DNA) |
| تواريخ الأحداث: | Date Created: 20210430 Date Completed: 20220401 Latest Revision: 20220416 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8530842 |
| DOI: | 10.1158/1078-0432.CCR-21-0410 |
| PMID: | 33926918 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-21-0410 |